RBC Capital analyst Ben Hendrix raised the firm’s price target on Tenet Healthcare (THC) to $253 from $252 and keeps an Outperform rating on the shares. The firm cites the company’s “solid” preliminary Q4 results anticipating adjusted EBITDA at the upper-end of its guidance range, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Regains Full Conifer Ownership in Strategic Deal
- Tenet Healthcare completes transaction with CommonSpirit Health
- Tenet Healthcare sees FY25 adjusted EBITDA at ‘upper end’ of $4.47B-$4.57B
- Wells says ‘Great Healthcare Plan’ lacks new onerous proposals
- Tenet Healthcare price target lowered to $230 from $233 at TD Cowen